NEW YORK, June 4 – Illumina said Monday that R. Scott Greer, chairman and CEO of Abgenix, had been elected to its board of directors.

"We are honored that Scott has agreed to join our board. He brings a solid record of leadership and accomplishment in the life sciences industry and his insight and experience will be a tremendous asset to the company," said Jay Flatley, Illumina’s CEO, said in a statement.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Science speaks with the University of Michigan's Jedidiah Carlson, who has tracked population genetic discussions at white nationalist sites.

Gene therapies could qualify for a faster US Food and Drug Administration approval process, according to Stat News.

NPR reports that the US House of Representatives has passed a bill to enable terminally ill patients access to experimental drugs.

In Genome Research this week: inversion variants mapped in human, non-human primate genomes; transcriptome profiling of maize, sorghum; and more.